Loxo Oncology Obtains $24,000,000 Series B Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a4f35300-a41c-4096-a4f0-f4cd2be21c75
Date
5/6/2014
Company Name
Loxo Oncology
Mailing Address
1 Landmark Square Stamford, CT 06901 USA
Company Description
Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations.
Website
http://www.loxooncology.com
Transaction Type
Venture Equity
Transaction Amount
$24,000,000
Transaction Round
Series B
Proceeds Purposes
With the proceeds from this financing, we are now in an even stronger position to advance our lead asset LOXO-101, currently in a Phase 1 dose escalation trial, and to expand our exciting discovery pipeline.
M&A Terms
Venture Investor
Venture Investor
Venture Investor